Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Single Arm Pilot Study of OncoSil™, Administered to Study Participants With Unresectable Locally Advanced Pancreatic Adenocarcinoma, Given in Combination With FOLFIRINOX or Gemcitabine+Nab-paclitaxel Chemotherapies

NCT03003078 is registered in ClinicalTrials.gov with OncoSil Medical Limited as lead sponsor.

NCT NCT03003078
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03003078 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Single Arm Pilot Study of OncoSil™, Administered to Study Participants With Unresectable Locally Advanced Pancreatic Adenocarcinoma, Given in Combination With FOLFIRINOX or Gemcitabine+Nab-paclitaxel Chemotherapies
Lead sponsor
OncoSil Medical Limited
Phase
Not applicable
Overall status
Completed
Start date
March 27, 2017
Completion date
July 31, 2020
Enrollment
50 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable locally advanced pancreatic carcinoma